title: Prospective Acid Reflux Study of Iran (PARSI): methodology and study design.
abstract: BACKGROUND
  Gastroesophageal reflux disease is a common and chronic disorder but long term, prospective studies of the fate of patients seeking medical advice are scarce. This is especially prominent when looking at non-erosive reflux disease (NERD) patients.
  
  
  METHODS
  We designed a prospective cohort to assess the long term outcome of GERD patients referring to gastroenterologists. Consecutive consenting patients, 15 years of age and older, presenting with symptoms suggestive of GERD referring to our outpatient clinics undergo a 30 minute interview. Upper gastrointestinal endoscopy is performed for them with protocol biopsies and blood samples are drawn. Patients are then treated according to a set protocol and followed regularly either in person or by telephone for at least 10 years.
  
  
  CONCLUSIONS
  Our data show that such a study is feasible and follow-ups, which are the main concern, can be done in a fairly reliable way to collect data. The results of this study will help to clarify the course of various subgroups of GERD patients after coming to medical attention and their response to treatment considering different variables. In addition, the basic symptoms and biological database will fuel further molecular epidemiologic studies.
authors.affiliation: Digestive Disease Research Center (DDRC), Shariati Hospital, Medical Sciences/University of Tehran, North Kargar Ave., Tehran, Iran. sianm@ams.ac.ir
authors.forename: Siavosh
authors.initials: S
authors.lastname: Nasseri-Moghaddam
authors.forename: Hadi
authors.initials: H
authors.lastname: Razjouyan
authors.forename: Seyed Maysam
authors.initials: SM
authors.lastname: Alimohamadi
authors.forename: Mansoureh
authors.initials: M
authors.lastname: Mamarabadi
authors.forename: Mohamad-Hamed
authors.initials: MH
authors.lastname: Ghotbi
authors.forename: Pardis
authors.initials: P
authors.lastname: Mostajabi
authors.forename: Amir-Ali
authors.initials: AA
authors.lastname: Sohrabpour
authors.forename: Masoud
authors.initials: M
authors.lastname: Sotoudeh
authors.forename: Behnoush
authors.initials: B
authors.lastname: Abedi
authors.forename: Azadeh
authors.initials: A
authors.lastname: Mofid
authors.forename: Mehdi
authors.initials: M
authors.lastname: Nouraie
authors.forename: Shahnaz
authors.initials: S
authors.lastname: Tofangchiha
authors.forename: Reza
authors.initials: R
authors.lastname: Malekzadeh
mesh_terms: D001706:Biopsy; D015897:Comorbidity; D004334:Drug Administration Schedule; D004943:Esophagogastric Junction / Q000473:pathology; D004947:Esophagus / Q000473:pathology; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000453:epidemiology; D016480:Helicobacter pylori; D006801:Humans; D007492:Iran / Q000453:epidemiology; D043183:Irritable Bowel Syndrome / Q000453:epidemiology; D008297:Male; D024821:Metabolic Syndrome / Q000453:epidemiology; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D010353:Patient Education as Topic; D010437:Peptic Ulcer / Q000453:epidemiology; D011446:Prospective Studies; D011788:Quality of Life; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D009853:Omeprazole